title: Effect of ketotifen in obese patients with type 2 diabetes mellitus.
abstract: OBJECTIVE
  Mast cells are found to be an important contributor in obesity induced insulin resistance. We evaluate the effect of ketotifen in obese patient with type 2 diabetes (T2DM) treated with glimepiride.
  
  
  METHODS
  In a randomized controlled study we recruited forty-eight obese patients with T2DM from Internal Medicine Department at Tanta University Hospital, Egypt. They were classified into three groups: group 1, those who received glimepiride (GL) 3mg/d alone; group 2, those who received GL 3mg/d+ketotifen 1mg once daily; and group 3, those who received GL 3mg/d+ketotifen 1mg twice daily. Fasting blood samples were obtained before and 12weeks after treatment for biochemical analysis of glycemic and inflammatory biomarkers. Data were statistically analyzed by paired Student's t-test and one way analysis of variance; p<0.05 was considered statistically significant.
  
  
  RESULTS
  The obtained data suggested that the addition of ketotifen in twice daily dose has a beneficial effect on all measured parameters except adiponectin. However, glimepiride plus ketotifen once daily only affected the level of inflammatory biomarkers without any significant effect on other parameters.
  
  
  CONCLUSIONS
  The co-administration of ketotifen twice daily plus glimepiride improves glycemic and inflammatory process in obese patients with T2DM.
authors.affiliation: Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Egypt.
authors.forename: Sahar M
authors.initials: SM
authors.lastname: El-Haggar
authors.affiliation: Internal Medicine Department, Faculty of Medicine, Tanta University, Egypt.
authors.forename: Wael F
authors.initials: WF
authors.lastname: Farrag
authors.affiliation: Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Egypt. Electronic address: Fedaa.eldeep@yahoo.com.
authors.forename: Fedaa A
authors.initials: FA
authors.lastname: Kotkata
mesh_terms: D001786:Blood Glucose / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007249:Inflammation / Q000097:blood / Q000150:complications / Q000188:drug therapy; D018836:Inflammation Mediators / Q000097:blood; D007333:Insulin Resistance; D007665:Ketotifen / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D013453:Sulfonylurea Compounds / Q000627:therapeutic use
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D018836:Inflammation Mediators; D013453:Sulfonylurea Compounds; C057619:glimepiride; D007665:Ketotifen
keywords: Inflammation; Ketotifen; Mast cells; Obesity; T2DM